Senseonics to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

GERMANTOWN, Md.–(BUSINESS WIRE)– Senseonics Holdings Inc.(NYSE-MKT: SENS), a medical technology company
focused on the development and commercialization of Eversense®, a
long-term, implantable continuous glucose monitoring (CGM) system for
people with diabetes, today announced the company plans to participate
in the Morgan Stanley 15^th Annual Global Healthcare
Conference in New York, NY.

Senseonics’ management is scheduled to present on Monday, September 11,
2017 at 1:40 PM ET. Interested parties may access a webcast of the
presentation on the “Investor Relations” section of the company’s
website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics’ first generation continuous glucose monitoring (CGM)
system, Eversense®, includes a small sensor, smart transmitter and
mobile application. Based on fluorescence sensing technology, the sensor
is designed to be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile device.
After insertion, the sensor is designed to continually and accurately
measure glucose levels.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170906005920/en/